Business Context and Reporting Period
This Form 8-K Current Report was filed by Akers Biosciences, Inc. on August 11, 2014. The filing addresses corporate governance changes effective as of the report date.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel appointments and does not contain financial performance data.
Material Changes
The primary material change reported is the appointment of Thomas J. Knox as Co-Chairman of the Board, effective August 11, 2014. Mr. Knox previously served as the Lead Director and was appointed to the board on July 1, 2013.
Management Commentary and Risks
The filing provides a detailed biography of Mr. Knox, highlighting his extensive experience in healthcare, insurance, and finance. Key roles include:
- CEO of Knox Consulting Group.
- Former CEO of United Healthcare of Pennsylvania (2004-2006).
- Former Chairman and CEO of Fidelity Insurance Group, Inc. (1999-2004).
- Former Chairman and CEO of Crusader Holding Corporation (1988-2000).
- Chairman of INDECS Corp and ORB Automotive Corporation, Ltd.
No specific risks, contingencies, or unusual items were disclosed in this filing.
Investor Verification Checklist
- Verify the official board composition and the specific duties assigned to the new Co-Chairman.
- Review the company's most recent Form 10-K for financial performance data, as this 8-K contains none.
- Confirm if this appointment triggers any changes in executive compensation arrangements or board committee assignments.